Literature DB >> 15031206

Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.

Maria L Jison1, Peter J Munson, Jennifer J Barb, Anthony F Suffredini, Shefali Talwar, Carolea Logun, Nalini Raghavachari, John H Beigel, James H Shelhamer, Robert L Danner, Mark T Gladwin.   

Abstract

In sickle cell disease, deoxygenation of intra-erythrocytic hemoglobin S leads to hemoglobin polymerization, erythrocyte rigidity, hemolysis, and microvascular occlusion. Ischemia-reperfusion injury, plasma hemoglobin-mediated nitric oxide consumption, and free radical generation activate systemic inflammatory responses. To characterize the role of circulating leukocytes in sickle cell pathogenesis we performed global transcriptional analysis of blood mononuclear cells from 27 patients in steady-state sickle cell disease (10 patients treated and 17 patients untreated with hydroxyurea) compared with 13 control subjects. We used gender-specific gene expression to validate human microarray experiments. Patients with sickle cell disease demonstrated differential gene expression of 112 genes involved in heme metabolism, cell-cycle regulation, antioxidant and stress responses, inflammation, and angiogenesis. Inducible heme oxygenase-1 and downstream proteins biliverdin reductase and p21, a cyclin-dependent kinase, were up-regulated, potentially contributing to phenotypic heterogeneity and absence of atherosclerosis in patients with sickle cell disease despite endothelial dysfunction and vascular inflammation. Hydroxyurea therapy did not significantly affect leukocyte gene expression, suggesting that such therapy has limited direct anti-inflammatory activity beyond leukoreduction. Global transcriptional analysis of circulating leukocytes highlights the intense oxidant and inflammatory nature of steady-state sickle cell disease and provides insight into the broad compensatory responses to vascular injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031206      PMCID: PMC5560446          DOI: 10.1182/blood-2003-08-2760

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

Review 1.  The role of cytokines in sickle cell disease.

Authors:  A C Makis; E C Hatzimichael; K L Bourantas
Journal:  Ann Hematol       Date:  2000-08       Impact factor: 3.673

2.  Hydroxyurea and sickle cell disease: a chance for every patient.

Authors:  Debra L Weiner; Carlo Brugnara
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

3.  Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF).

Authors:  S Vordermeier; S Singh; J Biggerstaff; P Harrison; H Grech; T C Pearson; D C Dumonde; K A Brown
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

Review 4.  Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium.

Authors:  R P Hebbel
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

5.  Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice.

Authors:  S F Yet; R Tian; M D Layne; Z Y Wang; K Maemura; M Solovyeva; B Ith; L G Melo; L Zhang; J S Ingwall; V J Dzau; M E Lee; M A Perrella
Journal:  Circ Res       Date:  2001-07-20       Impact factor: 17.367

6.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

7.  Biliverdin reductase: a major physiologic cytoprotectant.

Authors:  David E Baranano; Mahil Rao; Christopher D Ferris; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

8.  Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury.

Authors:  Leo E Otterbein; Brian S Zuckerbraun; Manabu Haga; Fang Liu; Ruiping Song; Anny Usheva; Christina Stachulak; Natalya Bodyak; R Neal Smith; Eva Csizmadia; Shivraj Tyagi; Yorihiro Akamatsu; Richard J Flavell; Timothy R Billiar; Edith Tzeng; Fritz H Bach; Augustine M K Choi; Miguel P Soares
Journal:  Nat Med       Date:  2003-01-21       Impact factor: 53.440

9.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

Review 10.  Regulation of X-chromosome inactivation in development in mice and humans.

Authors:  T Goto; M Monk
Journal:  Microbiol Mol Biol Rev       Date:  1998-06       Impact factor: 11.056

View more
  96 in total

1.  Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.

Authors:  Dhananjay K Kaul; Xiao-du Liu; Hee-Yoon Chang; Ronald L Nagel; Mary E Fabry
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

2.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

3.  Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.

Authors:  Nalini Raghavachari; Xiuli Xu; Amy Harris; Jose Villagra; Carolea Logun; Jennifer Barb; Michael A Solomon; Anthony F Suffredini; Robert L Danner; Gregory Kato; Peter J Munson; Sidney M Morris; Mark T Gladwin
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

Review 4.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

Review 5.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

6.  Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Ping Zhang; Fuad Abdulla; Phong Nguyen; Trevor Killeen; Pauline Xu; Gerry O'Sullivan; Karl A Nath; Gregory M Vercellotti
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

7.  Anomalous renal effects of tin protoporphyrin in a murine model of sickle cell disease.

Authors:  Julio P Juncos; Joseph P Grande; Narayana Murali; Anthony J Croatt; Luis A Juncos; Robert P Hebbel; Zvonimir S Katusic; Karl A Nath
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

8.  Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

Authors:  Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

9.  Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice.

Authors:  Trisha Dasgupta; Mary E Fabry; Dhananjay K Kaul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-09       Impact factor: 3.619

10.  Red Blood Cell Adhesion to Heme-Activated Endothelial Cells Reflects Clinical Phenotype in Sickle Cell Disease.

Authors:  Erdem Kucukal; Anton Ilich; Nigel S Key; Jane A Little; Umut A Gurkan
Journal:  Am J Hematol       Date:  2018-06-15       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.